NL-OMON46252
Completed
Phase 4
Multicenter, open-label study to assess the effects of Certolizumab Pegol on the reduction of anterior uveitis flares in axial spondyloarthritis subjects with a history of anterior uveitis (C-view) - C-View
CB Biopharma SPR0 sites10 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- anterior uveïtis flares in axial spondyloarthritis
- Sponsor
- CB Biopharma SPR
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The study population will be subjects \*18 years, with a documented diagnosis of adult onset axSpA as meeting the Assessment of SpondyloArthritis International Society (\[ASAS] criteria of at least 3 months\* symptom duration, and with active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \*4, and spinal pain \*4 on a 0 to 10 Numerical Rating Scale (NRS). Nonradiographic axSpA subjects must either have C Reactive Protein \> upper limit of normal (ULN) and /or current evidence of sacroiliitis on Magnetic Resonance Imaging taken within 3 months prior to Baseline (no confirmation by central reading) as defined by ASAS criteria and ankylosing spondylitis subjects must have evidence of sacroiliitis on an x\-ray taken within 12 months prior to Baseline meeting modified New York criteria according to the Investigator. Subjects must have a documented history of AU diagnosed by an ophthalmologist and have at least 2 AU flares in the past, of which at least 1 AU flare was in the last 12 months prior to Baseline.
- •Additionally, subjects must be HLA\-B27 positive (if known prior to Screening, no additional testing is to be performed; if unknown, testing is to be performed at Screening and checked at Baseline) and subjects must have been intolerant to or had an inadequate response to at least 2 Nonsteroidal Anti\-inflammatory drugs (NSAIDs). Inadequate response to an NSAID is defined as lack of response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the administered NSAID.
Exclusion Criteria
- •1\. The subject has previously participated in this study or has previously received CZP treatment in or outside of another clinical study. However rescreening is possible if prophylactic treatment for latent tuberculosis infection (LTBI) was to be given but the Screening Period exceeded the 12 weeks.
- •2\. The subject has participated in another study of an investigational medicinal product (IMP) (or a medical device) within the previous 3 months or is currently participating in another study of an IMP (or a medical device).
- •3\. The subject has a history of chronic alcohol or drug abuse.
- •4\. The subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject\*s ability to participate in this study.
- •5\. The subject has a known hypersensitivity to any components of CZP or a history of an adverse reaction to polyethylene glycol.
- •Axial SpA\-disease related exclusions
- •6\. Subjects must not have any other inflammatory arthritis (eg, rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, or fibromyalgia).
- •7\. Subjects must not have a secondary, noninflammatory condition that, in the Investigator\*s opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject\*s primary diagnosis of axSpA.
- •Ophthalmic exclusion criteria
- •8\. Any history of uveitis (eg, posterior, panuveitis) except for AU associated with axSpA.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2012-002563-10-GBBayer AG426
Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)EUCTR2012-002563-10-DEBayer HealthCare AG450
Active, not recruiting
Phase 1
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2012-002563-10-FRBayer HealthCare AG450
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-HUInternational Committee for Contraception Research of the Population Council2,200
Active, not recruiting
Not Applicable
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-SEInternational Committee for Contraception Research of the Population Council2,200